Application 209726
- Type
- ANDA
- Sponsor
- AMNEAL PHARMS CO
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM | TABLET;ORAL | 25MG;220MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209726-001 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM | 25MG;220MG | TABLET / ORAL | 2018-10-23 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-10-28 04:53 UTC | 2022-10 | A209726-001 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;220MG | TABLET / ORAL | 2018-10-23 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | A209726-001 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;220MG | TABLET / ORAL | 2018-10-23 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A209726-001 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;220MG | TABLET / ORAL | 2018-10-23 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A209726-001 | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | 25MG;220MG | TABLET / ORAL | 2018-10-23 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naproxen Sodium PM | NAPROXEN SODIUM | Strategic Sourcing Services LLC | 03a331d8-c957-4949-894f-51d9bd15e0d0 | 2025-08-20 | Warnings | 209726 ANDA209726 70677-0064 |
| Naproxen Sodium and Diphenhydramine HCl | NAPROXEN SODIUM AND DIPHENHYDRAMINE | Amneal Pharmaceuticals NY LLC | caca14cf-95f2-4c60-8bba-2154b8f353a3 | 2023-12-30 | Warnings | 209726 ANDA209726 69238-1422 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0363-0844 | All Night Pain Relief PM | Naproxen Sodium | Walgreens | ANDA | Current |
| 0363-0844 | All Night Pain Relief PM | Naproxen Sodium | Walgreens | ANDA | Current |
| 0363-0844 | All Night Pain Relief PM | Naproxen Sodium | Walgreens | ANDA | Current |
| 55315-844 | Naproxen Sodium PM | Naproxen Sodium | Freds Inc | ANDA | Current |
| 55315-844 | Naproxen Sodium PM | Naproxen Sodium | Freds Inc | ANDA | Current |
| 55910-854 | Naproxen Sodium PM | Naproxen Sodium | Dolgencorp, Inc. (DOLLAR GENERAL & REXALL) | ANDA | Current |
| 55910-854 | Naproxen Sodium PM | Naproxen Sodium | Dolgencorp, Inc. (DOLLAR GENERAL & REXALL) | ANDA | Current |
| 55910-854 | Naproxen Sodium PM | Naproxen Sodium | Dolgencorp, Inc. (DOLLAR GENERAL & REXALL) | ANDA | Current |
| 62011-0396 | Naproxen Sodium PM | Naproxen Sodium | Strategic Sourcing Services LLC | ANDA | Current |
| 62011-0396 | Naproxen Sodium PM | Naproxen Sodium | McKesson (Health Mart) | ANDA | Current |
| 62011-0396 | Naproxen Sodium PM | Naproxen Sodium | Strategic Sourcing Services LLC | ANDA | Current |
| 63868-411 | Naproxen PM | Naproxen Sodium | QUALITY CHOICE (Chain Drug Marketing Association) | ANDA | Current |
| 63868-411 | Naproxen PM | Naproxen Sodium | QUALITY CHOICE (Chain Drug Marketing Association) | ANDA | Current |
| 69238-1422 | Naproxen Sodium and Diphenhydramine HCl | Naproxen Sodium and Diphenhydramine | Amneal Pharmaceuticals NY LLC | ANDA | Current |
| 69238-1422 | Naproxen Sodium and Diphenhydramine HCl | Naproxen Sodium and Diphenhydramine | Amneal Pharmaceuticals LLC | ANDA | Current |
| 69238-1422 | Naproxen Sodium and Diphenhydramine HCl | Naproxen Sodium and Diphenhydramine | Amneal Pharmaceuticals NY LLC | ANDA | Current |
| 69238-1422 | Naproxen Sodium and Diphenhydramine HCl | Naproxen Sodium and Diphenhydramine | Amneal Pharmaceuticals NY LLC | ANDA | Current |
| 70677-0064 | Naproxen Sodium PM | Naproxen Sodium | Strategic Sourcing Services LLC | ANDA | Current |
| 70677-0064 | Naproxen Sodium PM | Naproxen Sodium | McKesson (Sunmark) | ANDA | Current |
| 70677-0064 | Naproxen Sodium PM | Naproxen Sodium | Strategic Sourcing Services LLC | ANDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 56477 | ORIG | 2018-11-15 |